Market Indices
Sector Heatmap
DMRA — Damora Therapeutics, Inc. Ordinary Shares
NasdaqDamora Therapeutics, Inc. Ordinary Shares
- O
- 20.55
- H
- 20.77
- L
- 19.59
- V
- 692.1K
DMRA — Latest News & Headlines
11 StoriesUsing personal funds, CEO Jennifer Jarrett buys Damora Therapeutics (DMRA) shares at $20.23 each. - Stock Titan
Using personal funds, CEO Jennifer Jarrett buys Damora Therapeutics (DMRA) shares at $20.23 each. Stock Titan
Insider Stock Purchases: September 28, 2026 - Quiver Quantitative
Insider Stock Purchases: September 28, 2026 Quiver Quantitative
DMRA Reiterates by Wedbush -- Price Target Maintained at $40 - GuruFocus
DMRA Reiterates by Wedbush -- Price Target Maintained at $40 GuruFocus
(DMRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
(DMRA) Movement Within Algorithmic Entry Frameworks Stock Traders Daily
CEO, President & Director of Damora Therapeutics Picks Up 2.5% More Stock - Simply Wall Street
CEO, President & Director of Damora Therapeutics Picks Up 2.5% More Stock Simply Wall Street
Guggenheim raises Damora Therapeutics price target on MF sales outlook - Investing.com
Guggenheim raises Damora Therapeutics price target on MF sales outlook Investing.com
Breaking News about Damora Therapeutics, Inc. - Ordinary Shares (Nasdaq:DMRA) - FinancialContent
Breaking News about Damora Therapeutics, Inc. - Ordinary Shares (Nasdaq:DMRA) FinancialContent
Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC Filing - marketscreener.com
Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC Filing marketscreener.com
Damora Therapeutics (DMRA) CEO Jennifer Jarrett Buys 12,500 Shar - GuruFocus
Damora Therapeutics (DMRA) CEO Jennifer Jarrett Buys 12,500 Shar GuruFocus
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com - Investing.com UK
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com Investing.com UK
Damora Therapeutics Advances CALR-Targeted Antibody Into Early Clinical Testing - TipRanks
Damora Therapeutics Advances CALR-Targeted Antibody Into Early Clinical Testing TipRanks